Eli Lilly and Company, Erl Wood Manor, Windlesham, Surrey GU20 6PH, United Kingdom.
Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA.
Pharmacol Biochem Behav. 2017 Oct;161:22-29. doi: 10.1016/j.pbb.2017.09.002. Epub 2017 Sep 6.
The forced swim test (FST) is a commonly used preclinical animal behavioural model for prediction of antidepressant activity in humans. While the FST may qualitatively predict efficacy, less is known about the quantitative translation of FST data to human efficacious doses. Assessing quantitative translation allows better predictions of human efficacious doses and a higher chance of success in the drug development process. Dose-response and time-course FST experiments were carried out on mice using four marketed antidepressants (citalopram, desipramine, bupropion, desvenlafaxine) in addition to ketamine, all with varying mechanisms of action. Population pharmacokinetic (PK)/pharmacodynamic (PD) analysis methods were applied to analyse the PK and immobility data, and the accuracy of the translation of FST data to human doses was evaluated using both area under the curve (AUC) and concentration-based approaches. The results showed that for the five antidepressants, average human AUC at clinically relevant doses were up to 38-fold higher than mouse AUC at doses associated with 50% of maximal efficacy in the FST (ED). Using a concentration approach, human peak and trough drug concentrations at clinically relevant doses were generally associated with concentrations of at least 65% (EC) and 20% (EC) of maximal effect in mice, respectively. The FST is a useful tool to predict antidepressant efficacy across a variety of drugs with different mechanisms of actions. However, human doses can be over-or under-predicted many fold when using the traditional approach of estimating based upon ED AUC in mice. It is recommended that a concentration approach be used, where concentrations associated with 80% (EC) and 30% (EC) of maximal effect in the mouse are used as general targets for human maximum and trough concentrations, respectively, in the prediction of clinically efficacious doses of new, potential antidepressant agents.
强迫游泳测试(FST)是一种常用于预测人类抗抑郁活性的临床前动物行为模型。虽然 FST 可能定性地预测疗效,但对于 FST 数据到人类有效剂量的定量转化知之甚少。评估定量转化可以更好地预测人类有效剂量,并提高药物开发过程中的成功率。使用四种市售抗抑郁药(西酞普兰、去甲替林、安非他酮、文拉法辛)以及具有不同作用机制的氯胺酮,在小鼠上进行了剂量反应和时间过程 FST 实验。应用群体药代动力学(PK)/药效动力学(PD)分析方法分析 PK 和不动数据,并使用 AUC 和基于浓度的方法评估将 FST 数据转化为人类剂量的准确性。结果表明,对于五种抗抑郁药,在临床相关剂量下,平均人体 AUC 比 FST 中与 50%最大疗效相关的小鼠 AUC 高 38 倍(ED)。使用浓度方法,在临床相关剂量下,人体峰和谷药物浓度通常与至少 65%(EC)和 20%(EC)的最大效应浓度相关,分别在小鼠中。FST 是一种有用的工具,可以预测具有不同作用机制的各种药物的抗抑郁疗效。然而,当使用基于小鼠 ED AUC 进行估计的传统方法时,人类剂量可能会被高估或低估许多倍。建议使用浓度方法,其中与小鼠中 80%(EC)和 30%(EC)最大效应相关的浓度分别用作人体最大和谷浓度的一般目标,以预测新的潜在抗抑郁剂的临床有效剂量。